Arcutis Presents New Long-Term Data Of Roflumilast Cream 0.15% For The Treatment Of Mild To Moderate Atopic Dermatitis In Adults And Children Down To Age 6 At The Revolutionizing Alopecia Areata, Vitiligo, And Eczema Conference
Portfolio Pulse from Benzinga Newsdesk
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) presented new long-term data on roflumilast cream 0.15% for treating mild to moderate atopic dermatitis in adults and children aged 6 and older. The study showed continued improvements in symptoms, including itch, over 56 weeks, with 66.2% of participants achieving a 75% improvement in Eczema Area and Severity Index (EASI-75). The cream was well-tolerated with no new safety signals.
June 10, 2024 | 6:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Arcutis Biotherapeutics presented positive long-term data for roflumilast cream 0.15%, showing significant improvements in atopic dermatitis symptoms over 56 weeks. The cream was well-tolerated with no new safety signals.
The positive long-term data for roflumilast cream 0.15% indicates strong efficacy and safety, which is likely to boost investor confidence and positively impact ARQT's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100